HXN-1021 / Earendil Labs - LARVOL DELTA

Preclinical Characterization of a Potent and Half-life Extended Anti-OX40L Antibody (AAAAI 2026) - "In a pharmacokinetics study, HXN-1021 showed a half-life of about 20 days, significantly longer than that of an Amlitelimab analogue, which showed a half-life of approximately 10 days in the same study. Conclusions HXN-1021 is a next-generation, half-life extended anti-OX40L antibody that has the potential to provide sustained therapeutic benefits for patients with atopic dermatitis and other inflammatory and autoimmune diseases. IND-enabling studies for HXN-1021 are currently underway."

Preclinical • Atopic Dermatitis • Dermatitis • Graft versus Host Disease • Immunology • TNFSF4